Actelion Pharmaceuticals Ltd reported a 7% decline in revenue for 2011 and a 21% rise in operating costs, which resulted in a 95% drop in operating profit and a net loss for the year. Pressure on revenues of CHF 1.8 billion arose from the strength of the Swiss franc.
